Srilata Anne, MD
Child & Adolescent Psychiatry · Birmingham, ALNPI 1164418398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 33.5% of the total. Reporting peaked in 2019 at $321 and has fallen 76.3% since, to $76 in 2025.
Across 78 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$389
- AbbVie$200
- Johnson & Johnson$175
- Sunovion Pharmaceuticals Inc.$91
- Neurocrine Biosciences, Inc.$88
- Alkermes, Inc.$55
- plus $163 from 7 others
What the payments were for
- Food & beverage$1,161100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $389 |
| AbbVie(2 entities) | 16 | $200 |
| Johnson & Johnson | 10 | $175 |
| Sunovion Pharmaceuticals Inc. | 4 | $91 |
| Neurocrine Biosciences, Inc. | 5 | $88 |
| Alkermes, Inc. | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Indivior Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,161 in reported general payments places this provider in the 65th percentile of 40 child & adolescent psychiatry providers in Alabama.
See all child & adolescent psychiatry providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 233 | $718,882 |
| Risperdal ConstaRisperidone Microspheres | 77 | $171,374 |
| Abilify MaintenaAripiprazole | 59 | $164,875 |
| AustedoDeutetrabenazine | 24 | $144,402 |
| FanaptIloperidone | 23 | $55,261 |
| Risperidone ErRisperidone Microspheres | 21 | $25,592 |
| CaplytaLumateperone Tosylate | 12 | $20,203 |
| Paliperidone ErPaliperidone | 115 | $16,488 |
| Haloperidol Decanoate | 191 | $12,875 |
| Lurasidone Hcl | 22 | $11,506 |
| Divalproex Sodium ErDivalproex Sodium | 147 | $7,334 |
| Benztropine Mesylate | 486 | $7,243 |
| Clozapine | 102 | $6,660 |
| Aripiprazole | 219 | $6,045 |
| Quetiapine Fumarate | 448 | $6,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $175 | $890,256310 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $389 | $164,87559 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $29 | $144,40224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 40 child & adolescent psychiatry providers in Alabama.
Other child & adolescent psychiatry in Birmingham
- Artie NelsonBirmingham$32K
- Karen CallahanBirmingham$5K
- Casey LowreyBirmingham$4K
- Elizabeth FergusonBirmingham$1K
- Stewart WaddellBirmingham$1K
- Abhishek WadhwaBirmingham$978
- Francisca MgbodileBirmingham$582
- James CullinanBirmingham$57
- Tom VaughanBirmingham$49
- Tolulope PetersBirmingham$35
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.